Po-Ju Lin1, Luke J Peppone1, Michelle C Janelsins1, Supriya G Mohile2, Charles S Kamen1, Ian R Kleckner1, Chunkit Fung2, Matthew Asare1, Calvin L Cole3, Eva Culakova1, Karen M Mustian4. 1. Department of Surgery, James P. Wilmot Cancer Institute, University of Rochester Medical Center, 265 Crittenden Blvd., Box CU 420658, Rochester, NY, 14642, USA. 2. Department of Medicine, University of Rochester Medical Center, 601 Elmwood Ave., Box 704, Rochester, NY, 14642, USA. 3. Department of Orthopaedics, University of Rochester Medical Center, 601 Elmwood Ave., Box 658, Rochester, NY, 14642, USA. 4. Department of Surgery, James P. Wilmot Cancer Institute, University of Rochester Medical Center, 265 Crittenden Blvd., Box CU 420658, Rochester, NY, 14642, USA. Karen_Mustian@URMC.Rochester.Edu.
Abstract
PURPOSE OF REVIEW: To (1) explain what yoga is, (2) summarize published literature on the efficacy of yoga for managing cancer treatment-related toxicities, (3) provide clinical recommendations on the use of yoga for oncology professionals, and (4) suggest promising areas for future research. RECENT FINDINGS: Based on a total of 24 phase II and one phase III clinical trials, low-intensity forms of yoga, specifically gentle hatha and restorative, are feasible, safe, and effective for treating sleep disruption, cancer-related fatigue, cognitive impairment, psychosocial distress, and musculoskeletal symptoms in cancer patients receiving chemotherapy and radiation and cancer survivors. Clinicians should consider prescribing yoga for their patients suffering with these toxicities by referring them to qualified yoga professionals. More definitive phase III clinical trials are needed to confirm these findings and to investigate other types, doses, and delivery modes of yoga for treating cancer-related toxicities in patients and survivors.
PURPOSE OF REVIEW: To (1) explain what yoga is, (2) summarize published literature on the efficacy of yoga for managing cancer treatment-related toxicities, (3) provide clinical recommendations on the use of yoga for oncology professionals, and (4) suggest promising areas for future research. RECENT FINDINGS: Based on a total of 24 phase II and one phase III clinical trials, low-intensity forms of yoga, specifically gentle hatha and restorative, are feasible, safe, and effective for treating sleep disruption, cancer-related fatigue, cognitive impairment, psychosocial distress, and musculoskeletal symptoms in cancerpatients receiving chemotherapy and radiation and cancer survivors. Clinicians should consider prescribing yoga for their patients suffering with these toxicities by referring them to qualified yoga professionals. More definitive phase III clinical trials are needed to confirm these findings and to investigate other types, doses, and delivery modes of yoga for treating cancer-related toxicities in patients and survivors.
Authors: Ann M Berger; Jean L Grem; Constance Visovsky; Heather A Marunda; Justin M Yurkovich Journal: Oncol Nurs Forum Date: 2010-11 Impact factor: 2.172
Authors: Joseph A Roscoe; Maralyn E Kaufman; Sara E Matteson-Rusby; Oxana G Palesh; Julie L Ryan; Sadhna Kohli; Michael L Perlis; Gary R Morrow Journal: Oncologist Date: 2007
Authors: James W Carson; Kimberly M Carson; Laura S Porter; Francis J Keefe; Victoria L Seewaldt Journal: Support Care Cancer Date: 2009-02-12 Impact factor: 3.603
Authors: Janet S Carpenter; Julie L Elam; Sheila H Ridner; Pam H Carney; Gloria J Cherry; Heather L Cucullu Journal: Oncol Nurs Forum Date: 2004-05 Impact factor: 2.172
Authors: Alyson B Moadel; Chirag Shah; Judith Wylie-Rosett; Melanie S Harris; Sapana R Patel; Charles B Hall; Joseph A Sparano Journal: J Clin Oncol Date: 2007-09-04 Impact factor: 44.544
Authors: R M Raghavendra; R Nagarathna; H R Nagendra; K S Gopinath; B S Srinath; B D Ravi; S Patil; B S Ramesh; R Nalini Journal: Eur J Cancer Care (Engl) Date: 2007-11 Impact factor: 2.520
Authors: Suzanne C Danhauer; Elizabeth L Addington; Lorenzo Cohen; Stephanie J Sohl; Marieke Van Puymbroeck; Natalia K Albinati; S Nicole Culos-Reed Journal: Cancer Date: 2019-04-01 Impact factor: 6.860
Authors: Julia E Inglis; Michelle C Janelsins; Eva Culakova; Karen M Mustian; Po-Ju Lin; Ian R Kleckner; Luke J Peppone Journal: Support Care Cancer Date: 2019-07-02 Impact factor: 3.603
Authors: Julia E Inglis; Po-Ju Lin; Sarah L Kerns; Ian R Kleckner; Amber S Kleckner; Daniel A Castillo; Karen M Mustian; Luke J Peppone Journal: Nutr Cancer Date: 2019-01-26 Impact factor: 2.900
Authors: Lori Minasian; Eileen Dimond; Myrtle Davis; Bishow Adhikari; Richard Fagerstrom; Carol Fabian; Justin Floyd; Joseph M Unger; Pamela S Douglas; Karen M Mustian; Eric J Chow; Steven Lipshultz; W Gregory Hundley; Saro Armenian; Bonnie Ky Journal: JACC CardioOncol Date: 2019-09-24
Authors: Po-Ju Lin; Ian R Kleckner; Kah Poh Loh; Julia E Inglis; Luke J Peppone; Michelle C Janelsins; Charles S Kamen; Charles E Heckler; Eva Culakova; Wilfred R Pigeon; Pavan S Reddy; Michael J Messino; Rakesh Gaur; Karen M Mustian Journal: Integr Cancer Ther Date: 2019 Jan-Dec Impact factor: 3.279
Authors: Shruti R Patel; Jacqueline Zayas; Jose R Medina-Inojosa; Charles Loprinzi; Elizabeth J Cathcart-Rake; Anjali Bhagra; Janet E Olson; Fergus J Couch; Kathryn J Ruddy Journal: Glob Adv Health Med Date: 2021-01-08
Authors: Gabriel Lopez; Alejandro Chaoul; Catherine Powers-James; Carol A Eddy; Smitha Mallaiah; Telma I Gomez; Janet L Williams; Qi Wei; Eduardo Bruera; Lorenzo Cohen Journal: Integr Cancer Ther Date: 2018-08-31 Impact factor: 3.279
Authors: Teresa Zetzl; Andre Pittig; Agnes Renner; Birgitt van Oorschot; Elisabeth Jentschke Journal: Support Care Cancer Date: 2021-06-22 Impact factor: 3.603